Clinical Trial Update: Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic and safety study evaluating once-daily raltegravir and atazanavir in HIV-1 infected patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ATAZANAVIR (atazanavir)
• Raltegravir (raltegravir)

Snippet

Sponsor: Radboud University Medical Center | Conditions: HIV Infection, HIV Infections | Phase 2 | Status: COMPLETED